• Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints

  Aer Therapeutics has announced that a Phase 2a trial of fexlamose (AER-01) inhalation solution in patients with moderate-to-severe COPD failed to meet primary or secondary endpoints and also demonstrated an increased incidence of adverse events… [Read more . . .]

• Blue Lake gets $5 million grant from the Gates Foundation for expansion of Phase 1/2a pediatric trial of intranasal vaccine against RSV

  Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… [Read more . . .]

• DDL 2026 will feature the launch of a new incubator

  This year’s Drug Delivery to the Lungs (DDL) meeting will introduce a few innovations to its regular program of scientific lectures, industry and poster exhibitions, including the new DDL Incubator. DDL 2026 will take place… [Read more . . .]

• Aptar Pharma acquires Pulmotree and its Kolibri mesh nebulizer

  Aptar Pharma announced that it has acquired Pulmotree, the developer of the Kolibri mesh nebulizer, which it refers to as a non-propellant liquid inhaler. The Kolibri nebulizer is a breath-activated, connected device that provides real-time… [Read more . . .]

• Aptar names Virginie Maes as incoming President of Aptar Pharma

  AptarGroup has announced that Virginie Maes, who is currently VP of Healthcare Flexibles at Amcor, will join the company as President of Aptar Pharma as of January 1, 2027.  Maes joined Amcor in 2016; her prior… [Read more . . .]

• Nano24 announces that Phase 2b trial of its EXO-CD24 inhaled exosome in ARDS met its primary endpoint

• FDA clears United Therapeutics IND for Phase 2 SUMMIT trial of treprostinil SMI in patients with PH-COPD

• Aptar Pharma’s LuerVax intranasal vaccine delivery device gets CE mark

• Liquidia settles with United Therapeutics, Yutrepia treprostinil DPI will continue to be available for PAH

• Aptar announces the addition of OINDP manufacturing capacity at its Mumbai, India facility

More news . . .